Rheumatoid Arthritis Saudi Database (RASD): Disease Characteristics and Remission Rates in a Tertiary Care Center

References

• Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev. 2005;4(3):130–136. doi:doi:10.1016/j.autrev.2004.09.002.15823498
   PubMed Web of Science ®Google Scholar
• Barhamain AS, Magliah RF, Shaheen MH, et al. The journey of rheumatoid arthritis patients: a review of reported lag times from the onset of symptoms. Open Access Rheumatol. 2017;9:139–150. doi:doi:10.2147/OARRR.S138830.28814904
   PubMed Web of Science ®Google Scholar
• Hussain W, Noorwali A, Janoudi N, et al. From symptoms to diagnosis: an observational study of the journey of rheumatoid arthritis patients in Saudi Arabia. Oman Med J. 2016;31(1):29–34. doi:doi:10.5001/omj.2016.06.26816566
   PubMedGoogle Scholar
• van der Linden MP, le Cessie S, Raza K, et al. Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum. 2010;62(12):3537–3546. doi:doi:10.1002/art.27692.20722031
   PubMed Web of Science ®Google Scholar
• Saag KG, Teng GG, Patkar NM, et al. American college of rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59(6):762–784. doi:doi:10.1002/art.23721.18512708
   PubMed Web of Science ®Google Scholar
• Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the incidence of rheumatoid arthritis rising? Results from Olmsted County, Minnesota, 1955–2007. Arthritis Rheum. 2010;62(6):1576–1582. doi:doi:10.1002/art.27425.20191579
   PubMed Web of Science ®Google Scholar
• Weyand CM, Schmidt D, Wagner U, Goronzy JJ. The influence of sex on the phenotype of rheumatoid arthritis. Arthritis Rheum. 1998;41(5):817–822. doi:doi:10.1002/1529-0131(199805)41:5<817::aid-art7>3.0.CO;2-S.9588732
   PubMed Web of Science ®Google Scholar
• Yu C, Jin S, Wang Y, et al. Remission rate and predictors of remission in patients with rheumatoid arthritis under treat-to-target strategy in real-world studies: a systematic review and meta-analysis. Clin Rheumatol. 2019;38(3):727–738. doi:doi:10.1007/s10067-018-4340-7.30341703
   PubMed Web of Science ®Google Scholar
• Masi AT, Maldonado-Cocco JA, Kaplan SB, Feigenbaum SL, Chandler RW. Prospective study of the early course of rheumatoid arthritis in young adults: comparison of patients with and without rheumatoid factor positivity at entry and identification of variables correlating with outcome. Semin Arthritis Rheum. 1976;4(4):299–326. doi:doi:10.1016/0049-0172(76)90013-5.1273600
   PubMedGoogle Scholar
• Darawankul B, Chaiamnuay S, Pakchotanon R, Asavatanabodee P, Narongroeknawin P. The good EULAR response at the first year is strongly predictive of clinical remission in rheumatoid arthritis: results from the TARAC cohort. Clin Rheumatol. 2015;34(1):43–49. doi:doi:10.1007/s10067-014-2749-1.25060487
   PubMed Web of Science ®Google Scholar
• Mierau M, Schoels M, Gonda G, Fuchs J, Aletaha D, Smolen JS. Assessing remission in clinical practice. Rheumatology (Oxford). 2007;46(6):975–979. doi:doi:10.1093/rheumatology/kem00717341506
   PubMed Web of Science ®Google Scholar
• Barnabe C, Homik J, Barr SG, Martin L, Maksymowych WP. The effect of different remission definitions on identification of predictors of both point and sustained remission in rheumatoid arthritis treated with anti-TNF therapy. J Rheumatol. 2014;41(8):1607–1613. doi:doi:10.3899/jrheum.131451.25028371
   PubMed Web of Science ®Google Scholar
• Lukas C, Combe B, Ravaud P, Sibilia J, Landew R, van der Heijde D. Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: data from the Étude et Suivi des polyarthrites indifférenciées récentes (study and followup of early undifferentiated polyarthritis). Arthritis Rheum. 2011;63(7):1804–1811. doi:doi:10.1002/art.30371.21452295
   PubMed Web of Science ®Google Scholar
• Dargham SR, Zahirovic S, Hammoudeh M, et al. Correction: epidemiology and treatment patterns of rheumatoid arthritis in a large cohort of Arab patients. PLoS One. 2019;14(3):e0214258. doi:doi:10.1371/journal.pone.0214258.30883600
   PubMed Web of Science ®Google Scholar
• Emery P, Kvien TK, Combe B, et al. Combination etanercept and methotrexate provides better disease control in very early (≤4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the comet study. Ann Rheum Dis. 2012;71(6):989–992. doi:doi:10.1136/annrheumdis-2011-201066.22402142
   PubMed Web of Science ®Google Scholar
• Zafar S, Badsha H, Mofti A, et al. Efforts to increase public awareness may result in more timely diagnosis of rheumatoid arthritis. J Clin Rheumatol. 2012;18(6):279–282. doi:doi:10.1097/RHU.0b013e3182676975.22955475
   PubMed Web of Science ®Google Scholar
• Raza K, Stack R, Kumar K, et al. Delays in assessment of patients with rheumatoid arthritis: variations across Europe. Ann Rheum Dis. 2011;70(10):1822–1825. doi:doi:10.1136/ard.2011.151902.21821867
   PubMed Web of Science ®Google Scholar
• Sørensen J, Hetland ML, all departments of rheumatology in Denmark. Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry. Ann Rheum Dis. 2015;74(3):e12. doi:doi:10.1136/annrheumdis-2013-204867.24534758
   PubMed Web of Science ®Google Scholar
• Raciborski F, Kłak A, Kwiatkowska B, et al. Diagnostic delays in rheumatic diseases with associated arthritis. Reumatologia. 2017;55(4):169–176. doi:doi:10.5114/reum.2017.69777.29056771
   PubMedGoogle Scholar
• Kuriya B, Xiong J, Boire G, et al. Earlier time to remission predicts sustained clinical remission in early rheumatoid arthritis–results from the Canadian early arthritis cohort (CATCH). J Rheumatol. 2014;41(11):2161–2166. doi:doi:10.3899/jrheum.140137.25274902
   PubMed Web of Science ®Google Scholar
• Raza K, Buckley CE, Salmon M, Buckley CD. Treating very early rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2006;20(5):849–863. doi:doi:10.1016/j.berh.2006.05.00516980210
   PubMed Web of Science ®Google Scholar
• Almoallim H, Janoudi N, Attar SM, et al. Determining early referral criteria for patients with suspected inflammatory arthritis presenting to primary care physicians: a cross-sectional study. Open Access Rheumatol. 2017;9:81–90. doi:doi:10.2147/OARRR.S134780.28490909
   PubMed Web of Science ®Google Scholar
• Hetland ML, Christensen IJ, Tarp U, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010;62(1):22–32. doi:doi:10.1002/art.27227.20039405
   PubMed Web of Science ®Google Scholar
• Kristensen LE, Kapetanovic MC, Gülfe A, Söderlin M, Saxne T, Geborek P. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish arthritis treatment group register. Rheumatology (Oxford). 2008;47(4):495–499. doi:doi:10.1093/rheumatology/ken002.18316338
   PubMed Web of Science ®Google Scholar
• Mariette X, Gottenberg JE, Ravaud P, Combe B. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology (Oxford). 2011;50(1):222–229. doi:doi:10.1093/rheumatology/keq368.21148156
   PubMed Web of Science ®Google Scholar
• Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38(9):1261–1265. doi:doi:10.1086/383317.15127338
   PubMed Web of Science ®Google Scholar
• Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy. Arthritis Rheum. 2009;60(7):1884–1894. doi:doi:10.1002/art.24632.19565495
   PubMed Web of Science ®Google Scholar
• Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British society for rheumatology biologics register (BSRBR). Ann Rheum Dis. 2010;69(3):522–528. doi:doi:10.1136/ard.2009.118935.19854715
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Park SH, Gul A, et al. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(6):1133–1138. doi:doi:10.1136/annrheumdis-2015-207319.26318385
   PubMed Web of Science ®Google Scholar
• Navarra SV, Tang B, Lu L, et al. Risk of tuberculosis with anti-tumor necrosis factor-α therapy: substantially higher number of patients at risk in Asia. Int J Rheum Dis. 2014;17(3):291–298. doi:doi:10.1111/1756-185X.12188.24131578
   PubMed Web of Science ®Google Scholar
• Alkadi A, Alduaiji N, Alrehaily A. Risk of tuberculosis reactivation with rituximab therapy. Int J Health Sci (Qassim). 2017;11(2):41–44.28539862
   PubMedGoogle Scholar
• Mariette X, Tubach F, Bagheri H, et al. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis. 2010;69(2):400–408. doi:doi:10.1136/ard.2009.117762.19828563
   PubMed Web of Science ®Google Scholar
• Franklin JP, Symmons DP, Silman AJ. Risk of lymphoma in patients with RA treated with anti-TNFalpha agents. Ann Rheum Dis. 2005;64(5):657–658. doi:doi:10.1136/ard.2005.035311.15834052
   PubMed Web of Science ®Google Scholar
• Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the food and drug administration. Arthritis Rheum. 2002;46(12):3151–3158. doi:doi:10.1002/art.10679.12483718
   PubMed Web of Science ®Google Scholar
• Mercer LK, Galloway JB, Lunt M, et al. Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British society for rheumatology biologics register for rheumatoid arthritis. Ann Rheum Dis. 2017;76(3):497–503. doi:doi:10.1136/annrheumdis-2016-209389.27502891
   PubMed Web of Science ®Google Scholar
• Parikh-Patel A, White RH, Allen M, Cress R. Risk of cancer among rheumatoid arthritis patients in California. Cancer Causes Control. 2005;64(5):1001–1010. doi:10.1136/ard.2005.035311
   Web of Science ®Google Scholar